Barry J. Plant

Barry J. Plant

Auto-generated profile, based on publicly available information

Barry J. Plant

Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Cork, Ireland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2017 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
DBD.G. Burke
D.G. Burke
FFF. Fouhy
F. Fouhy
MHM. J. Harrison
M. J. Harrison
MRM. C. Rea
M. C. Rea
PCPaul Cotter
Paul Cotter
RRR. Paul Ross
R. Paul Ross
Cystic Fibrosis (CF) is an autosomal recessive disease that affects the function of a number of organs, principally the lungs, but also the gastrointestinal tract. The manifestations of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction in the gastrointestinal tract, as well as frequent antibiotic exposure, undoubtedly disrupts the gut microbiota. To analyse the effects of CF and its management on the microbiome, we compared the gut microbiota of 43 individuals with CF during a period of stability, to that of 69 non-CF controls using 454-pyrosequencing of the 16S rRNA gene. The impact of clinical parameters, including antibiotic therapy, on the results was also assessed. The CF-associated microbiome had reduced microbial diversity, an increase in Firmicutes and a reduction in Bacteroidetes compared to the non-CF controls. While the greatest number of differences in taxonomic abundances of the intestinal microbiota was observed between individuals with CF and the healthy controls, gut microbiota differences were also reported between people with CF when grouped by clinical parameters including % predicted FEV1 (measure of lung dysfunction) and the number of intravenous (IV) antibiotic courses in the previous 12 months. Notably, CF individuals presenting with severe lung dysfunction (% predicted FEV1 ≤ 40%) had significantly (p < 0.05) reduced gut microbiota diversity relative to those presenting with mild or moderate dysfunction. A significant negative correlation (−0.383, Simpson’s Diversity Index) was also observed between the number of IV antibiotic courses and gut microbiota diversity. This is one of the largest single-centre studies on gut microbiota in stable adults with CF and demonstrates the significantly altered gut microbiota, including reduced microbial diversity seen in CF patients compared to healthy controls. The data show the impact that CF and it's management have on gut microbiota, presenting the opportunity to develop CF specific probiotics to minimise microbiota alterations.

16 January 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
PNEUMOLOGIE BurgelPNEUMOLOGIE Burgel
PNEUMOLOGIE Burgel
KSKevin Southern
Kevin Southern
CACharlotte Addy
Charlotte Addy
ABAlberto Battezzati
Alberto Battezzati
CBClaire Berry
Claire Berry
PMPeter Middleton
Peter Middleton
This is the third in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on recognising and addressing CF health issues. The guidance was produced with wide stakeholder engagement, including people from the CF community, using an evidence-based framework. Authors contributed sections, and summary statements which were reviewed by a Delphi consultation. Monitoring and treating airway infection, inflammation and pulmonary exacerbations remains important, despite the widespread availability of CFTR modulators and their accompanying health improvements. Extrapulmonary CF-specific health issues persist, such as diabetes, liver disease, bone disease, stones and other renal issues, and intestinal obstruction. These health issues require multidisciplinary care with input from the relevant specialists. Cancer is more common in people with CF compared to the general population, and requires regular screening. The CF life journey requires mental and emotional adaptation to psychosocial and physical challenges, with support from the CF team and the CF psychologist. This is particularly important when life gets challenging, with disease progression requiring increased treatments, breathing support and potentially transplantation. Planning for end of life remains a necessary aspect of care and should be discussed openly, honestly, with sensitivity and compassion for the person with CF and their family. CF teams should proactively recognise and address CF-specific health issues, and support mental and emotional wellbeing while accompanying people with CF and their families on their life journey.

1 February 2018 in Chest
Verified
Journal Article
Open access
NRNicola J. Ronan
Nicola J. Ronan
GEGisli G. Einarsson
Gisli G. Einarsson
MTMaria Twomey
Maria Twomey
DMDenver Mooney
Denver Mooney
DMDavid Mullane
David Mullane
BPBarry J. Plant
Barry J. Plant
Ivacaftor produces significant clinical benefit in patients with cystic fibrosis (CF) with the G551D mutation. Prevalence of this mutation at the Cork CF Centre is 23%. This study assessed the impact of cystic fibrosis transmembrane conductance regulator modulation on multiple modalities of patient assessment. Thirty-three patients with the G551D mutation were assessed at baseline and prospectively every 3 months for 1 year after initiation of ivacaftor. Change in ultra-low-dose chest CT scans, blood inflammatory mediators, and the sputum microbiome were assessed. Significant improvements in FEV1, BMI, and sweat chloride levels were observed post-ivacaftor treatment. Improvement in ultra-low-dose CT imaging scores were observed after treatment, with significant mean reductions in total Bhalla score (P < .01), peribronchial thickening (P = .035), and extent of mucous plugging (P < .001). Reductions in circulating inflammatory markers, including interleukin (IL)-1β, IL-6, and IL-8 were demonstrated. There was a 30% reduction in the relative abundance of Pseudomonas species and an increase in the relative abundance of bacteria associated with more stable community structures. Posttreatment community richness increased significantly (P = .03). Early and sustained improvements on ultra-low-dose CT scores suggest it may be a useful method of evaluating treatment response. It paralleled improvement in symptoms, circulating inflammatory markers, and changes in the lung microbiota.

1 June 2017 in La Presse Médicale
Verified
Journal Article
Closed access
NRNicola J. Ronan
Nicola J. Ronan
JEJoseph Stuart Elborn
Joseph Stuart Elborn
BPBarry J. Plant
Barry J. Plant

1 December 2014 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
MHM.J. Harrison
M.J. Harrison
MMM. McCarthy
M. McCarthy
CFC. Fleming
C. Fleming
CHC. Hickey
C. Hickey
CSC. Shortt
C. Shortt
BPB.J. Plant
B.J. Plant

26 September 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MHMichael J. Harrison
Michael J. Harrison
DMDesmond M. Murphy
Desmond M. Murphy
BPBarry J. Plant
Barry J. Plant
Recent studies provide support for the usefulness of the oral potentiator ivacaftor in patients with cystic fibrosis who are heterozygous for the G551D mutation.1 The possibility of an increased response in persons who are homozygous for the mutation is unknown because of its low prevalence. Ivacaftor potentiates the open-channel probability of the G551D–cystic fibrosis transmembrane conductance regulator (CFTR) protein.1 The most common cystic fibrosis mutation, F508del, results in little or no CFTR reaching the cell surface, whereas with the G551D-CFTR mutation, there are potentially normal levels of nonfunctional CFTR channels at the cell surface.2 Therefore, we postulate the increased efficacy of ivacaftor in G551D homozygotes as compared with compound heterozygotes with a single G551D mutation. Furthermore, little is known about the response to ivacaftor in persons with a forced expiratory volume in 1 second (FEV1) of less than 30% of the predicted value, because these persons were excluded from initial studies.1,3